BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 26397226)

  • 1. APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls.
    Sampedro F; Vilaplana E; de Leon MJ; Alcolea D; Pegueroles J; Montal V; Carmona-Iragui M; Sala I; Sánchez-Saudinos MB; Antón-Aguirre S; Morenas-Rodríguez E; Camacho V; Falcón C; Pavía J; Ros D; Clarimón J; Blesa R; Lleó A; Fortea J;
    Oncotarget; 2015 Sep; 6(29):26663-74. PubMed ID: 26397226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
    Chételat G; Fouquet M
    Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.
    Mosconi L; De Santi S; Brys M; Tsui WH; Pirraglia E; Glodzik-Sobanska L; Rich KE; Switalski R; Mehta PD; Pratico D; Zinkowski R; Blennow K; de Leon MJ
    Biol Psychiatry; 2008 Mar; 63(6):609-18. PubMed ID: 17720148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease.
    Fortea J; Vilaplana E; Alcolea D; Carmona-Iragui M; Sánchez-Saudinos MB; Sala I; Antón-Aguirre S; González S; Medrano S; Pegueroles J; Morenas E; Clarimón J; Blesa R; Lleó A;
    Ann Neurol; 2014 Aug; 76(2):223-30. PubMed ID: 24852682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern.
    Risacher SL; Kim S; Nho K; Foroud T; Shen L; Petersen RC; Jack CR; Beckett LA; Aisen PS; Koeppe RA; Jagust WJ; Shaw LM; Trojanowski JQ; Weiner MW; Saykin AJ;
    Alzheimers Dement; 2015 Dec; 11(12):1417-1429. PubMed ID: 25960448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of sex and APOE ε4 with brain tau deposition and atrophy in older adults with Alzheimer's disease.
    Yan S; Zheng C; Paranjpe MD; Li J; Benzinger TLS; Lu J; Zhou Y
    Theranostics; 2020; 10(23):10563-10572. PubMed ID: 32929366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.
    Voevodskaya O; Sundgren PC; Strandberg O; Zetterberg H; Minthon L; Blennow K; Wahlund LO; Westman E; Hansson O;
    Neurology; 2016 May; 86(19):1754-61. PubMed ID: 27164711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
    Kester MI; Blankenstein MA; Bouwman FH; van Elk EJ; Scheltens P; van der Flier WM
    J Alzheimers Dis; 2009; 16(3):601-7. PubMed ID: 19276554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrinsic functional connectivity alterations in cognitively intact elderly APOE ε4 carriers measured by eigenvector centrality mapping are related to cognition and CSF biomarkers: a preliminary study.
    Luo X; Qiu T; Jia Y; Huang P; Xu X; Yu X; Shen Z; Jiaerken Y; Guan X; Zhou J; Zhang M;
    Brain Imaging Behav; 2017 Oct; 11(5):1290-1301. PubMed ID: 27714554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status.
    Reas ET; Triebswetter C; Banks SJ; McEvoy LK
    Alzheimers Res Ther; 2024 Jan; 16(1):7. PubMed ID: 38212861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome.
    Bejanin A; Iulita MF; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernandez S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Padilla C; Aranha MR; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Zetterberg H; Blennow K; Alcolea D; Clarimon J; Zaman SH; Blesa R; Lleó A; Fortea J
    JAMA Neurol; 2021 Aug; 78(8):937-947. PubMed ID: 34228042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Ayutyanont N; Roontiva A; Thiyyagura P; Protas H; Joshi AD; Sabbagh M; Sadowsky CH; Sperling RA; Clark CM; Mintun MA; Pontecorvo MJ; Coleman RE; Doraiswamy PM; Johnson KA; Carpenter AP; Skovronsky DM; Reiman EM
    Neurobiol Aging; 2013 Jan; 34(1):1-12. PubMed ID: 22633529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4.
    Belloy ME; Napolioni V; Han SS; Le Guen Y; Greicius MD;
    JAMA Neurol; 2020 Jul; 77(7):849-862. PubMed ID: 32282020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study.
    Mosconi L; Sorbi S; Nacmias B; De Cristofaro MT; Fayyaz M; Bracco L; Herholz K; Pupi A
    Psychiatry Res; 2004 Feb; 130(2):141-51. PubMed ID: 15033184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.
    Saddiki H; Fayosse A; Cognat E; Sabia S; Engelborghs S; Wallon D; Alexopoulos P; Blennow K; Zetterberg H; Parnetti L; Zerr I; Hermann P; Gabelle A; Boada M; Orellana A; de Rojas I; Lilamand M; Bjerke M; Van Broeckhoven C; Farotti L; Salvadori N; Diehl-Schmid J; Grimmer T; Hourregue C; Dugravot A; Nicolas G; Laplanche JL; Lehmann S; Bouaziz-Amar E; ; Hugon J; Tzourio C; Singh-Manoux A; Paquet C; Dumurgier J
    PLoS Med; 2020 Aug; 17(8):e1003289. PubMed ID: 32817639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism.
    Yi D; Lee Y; Byun MS; Lee JH; Ko K; Sohn BK; Choe YM; Choi HJ; Baek H; Sohn CH; Kim YK; Lee DY;
    Alzheimers Res Ther; 2018 Aug; 10(1):84. PubMed ID: 30134963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.